Philips to distribute Corindus robotic-assisted PCI system

| | Health Exec | Artificial Intelligence
Robotics - 164.83 Kb
Corindus Vascular Robotics receives FDA 510(k) clearance for the CorPath 200 System to assist interventional cardiologists in performing PCI. Source: Corindus Vascular Robotics
Royal Philips Electronics and Corindus Vascular Robotics have signed a U.S. distribution agreement for Corindus’ CorPath 200 system, the recently FDA-approved robotic-assisted system to be used during PCI procedures.

The financial details of the exclusive distribution agreement were not disclosed. Philips owns a minority share in the Natick, Mass.-based Corindus, which commercializes robotic-assisted systems for interventional cardiology procedures.

The CorPath 200 system can be integrated with x-ray fluoroscopy systems including Philips’ Allura x-ray equipment. The robotic-assisted system can be used with standard stents, catheters and guidewires, the companies said in a press release. The CorPath 200 system is operated by the interventional cardiologist from a radiation shielded, interventional cockpit.

The distribution agreement enables both companies to sell the robotic-assisted system in the U.S.

Related Content

Advancing AI for vascular surgery will require a commitment to data integrity
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
New AI program delivers rapid, accurate echo video assessments
ICU diary-keeping: There’s an AI for that
FDA commissioner urges health systems to strengthen AI quality oversight

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.